A study by researchers at the University of Western Australia and the Telethon Kids Institute found that a drug that helps people refrain from drinking alcohol showed no harmful effects during pregnancy in early-stage trials.
A study of the effects of acamprosate on maternal and neonatal outcomes in a mouse model of alcohol use disorder, published in Physiology & Behavior, found that acamprosate, one of many pharmacotherapies used to treat alcohol use disorders, examined the safety of naltrexone.
The drug was found to have no effect on maternal and birth outcomes, postnatal offspring weight, or motor control.
Researcher Ebony Quintrell, a doctoral candidate in the Department of Population and Global Health at UWA, said finding effective, evidence-based treatments for pregnant women with alcoholism is a challenge.
“Many medications, including acamprosate, are commonly used to maintain abstinence, but are generally not recommended for use during pregnancy,” Quintrell said.
“Thus, pregnant women are expected to abstain from drinking completely without medication assistance, due to lack of evidence, and this can be physiologically and psychologically difficult.
Alcohol is known to cause birth defects in fetal development, but Quintrell said it was important to test the safety of drugs that help alcohol use disorders during pregnancy. This is an area of research that has often been neglected.
“Many women who needed medication for their pre-pregnancy conditions and then become pregnant are left with no choice because of the lack of information at a time when solid safety information is most needed,” she said. Told.
More research was needed before this drug gave pregnant women the green light.